Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986214 | 0.93 | TDP1 (0.34) | HTR4PTGDR2ALDH1A1TSHR | |
| SCHEMBL2997066 | 0.92 | HTR4 (0.34) | HTR4PTGDR2 | |
| SCHEMBL2988515 | 0.90 | GSK3B (0.35) | PTGDR2ALDH1A1TSHRKCNH2 | |
| SCHEMBL2993561 | 0.88 | PTGDR2 (0.32) | HTR4HTR6PTGDR2ADRA1A | |
| SCHEMBL2986343 | 0.88 | HTR6 (0.34) | HTR6PTGDR2CYP2D6KMT2A | |
| SCHEMBL1748699 | 0.88 | TP53 (0.36) | HTR4HTR6PTGDR2HTR2AHTR2C | |
| SCHEMBL2993349 | 0.86 | PTGDR2 (0.36) | PTGDR2 | |
| SCHEMBL2997504 | 0.86 | HTR6 (0.37) | PDE5AHTR6PTGDR2ALDH1A1TSHR | |
| SCHEMBL2992606 | 0.86 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL2985976 | 0.85 | MKNK2 (0.37) | HTR6PTGDR2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799691-B1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | HTR4 2236/4885PDE5A 822/4885HTR6 1962/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | HTR4 2236/4885PDE5A 822/4885HTR6 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.